

February 25, 2026

To,
BSE Ltd
PJ Towers,
Dalal Street,
Mumbai – 400001.
BSE Scrip Code: 532372

To,
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla
Complex, Bandra, East, Mumbai –
400051
NSE Symbol: VIRINCHI

To,
Virinchi Limited
8-2-672 / 5 & 6, 4th Floor,
Ilyas Mohammed Khan
Estate, Road No.1, Banjara
Hills, Hyderabad,
Telangana – 500034.

Dear Sir/Madam,

Sub: - Reporting under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011


With reference to the above, please find enclosed reporting under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 pursuant to the allotment of 13,15,715 equity shares on conversion of warrants issued on preferential basis in Virinchi Limited on February 24, 2026.

This is for your information and records.

Thanking you

Yours Truly



For Vivo Bio Tech Limited


Kalyan Ram Mangipudi
Whole-time Director
02012580



Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Virinchi Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Vivo Bio tech Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes, Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited NSE Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	37,84,285	3.48	3.00
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others	-	-	-
c) Voting rights (VR) otherwise than by equity shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	1,22,15,715	11.23	9.69
e) Total (a+b+c+d)	1,60,00,000	14.71	12.69
Details of acquisition:			
a) Shares carrying voting rights acquired	13,15,715	1.21	1.04
b) VRs acquired otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	(13,15,715)	(1.21)	(1.04)
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+/-d)	-	-	-





After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	51,00,000	4.69	4.05
b) VRs otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	1,09,00,000	10.02	8.65
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
e) Total (a+b+c+d)	1,60,00,000	14.71	12.69
Mode of acquisition (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	Conversion of Warrants into Equity Shares		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	February 24, 2026		
Equity share capital / total voting capital of the TC before the said acquisition	10,87,96,896 Equity shares of Rs. 10 each aggregating Rs. 108,79,68,960/-		
Equity share capital/ total voting capital of the TC after the said acquisition	10,87,96,896 Equity shares of Rs. 10 each aggregating Rs. 108,79,68,960/-		
Total diluted share/voting capital of the TC after the said acquisition	12,60,46,896 Equity shares of Rs. 10 each aggregating Rs. 126,04,68,960*		


Diluted Share Capital:

*The above Equity share capital is based on the assumption of 1,72,50,000 outstanding Warrants shall be converted into equity shares, in one or more tranches.

For Vivo Bio Tech Limited



Kalyan Ram Mangipudi
Whole-time Director
02012580



Place: Hyderabad

Date: February 25, 2026